Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and glucose, (beta-d)-isomer

sorafenib has been researched along with glucose, (beta-d)-isomer in 4 studies

Compound Research Comparison

Studies
(sorafenib)		Trials
(sorafenib)		Recent Studies (post-2010)
(sorafenib)		Studies
(glucose, (beta-d)-isomer)		Trials
(glucose, (beta-d)-isomer)		Recent Studies (post-2010) (glucose, (beta-d)-isomer)
6,5207305,25121,95688310,747

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (50.00)24.3611
2020's2 (50.00)2.80

Authors

AuthorsStudies
Rupasinghe, HV; Sudan, S1
Dai, Z; Deng, Y; Dong, L; Liang, L; Zan, Y1
Chen, M; Liu, L; Ma, D; Wang, J; Wang, Z1
Cui, Y; Dong, Z; Fu, Y; He, X; Li, Y; Ma, Y; Xun, X1

Other Studies

4 other study(ies) available for sorafenib and glucose, (beta-d)-isomer

ArticleYear
Antiproliferative activity of long chain acylated esters of quercetin-3-O-glucoside in hepatocellular carcinoma HepG2 cells.
    Experimental biology and medicine (Maywood, N.J.), 2015, Volume: 240, Issue:11

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell Cycle; Cell Proliferation; Cisplatin; DNA Fragmentation; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Esters; Fatty Acids; Flavonoids; Glucosides; Hep G2 Cells; Humans; Liver Neoplasms; Microscopy, Fluorescence; Niacinamide; Phenylurea Compounds; Quercetin; Sorafenib

2015
Co-delivery of plantamajoside and sorafenib by a multi-functional nanoparticle to combat the drug resistance of hepatocellular carcinoma through reprograming the tumor hypoxic microenvironment.
    Drug delivery, 2019, Volume: 26, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Catechols; Cell Line, Tumor; Cell-Penetrating Peptides; Drug Resistance, Neoplasm; Glucosides; Hep G2 Cells; Humans; Hypoxia; Liver Neoplasms; Mice; Nanoparticles; Sorafenib; Tumor Microenvironment; Xenograft Model Antitumor Assays

2019
Acteoside as a potential therapeutic option for primary hepatocellular carcinoma: a preclinical study.
    BMC cancer, 2020, Sep-29, Volume: 20, Issue:1

    Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glucosides; Hep G2 Cells; Humans; Kallikreins; Liver Neoplasms; Mice; Neovascularization, Pathologic; Phenols; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2020
Development of UPLC-MS/MS Method to Study the Pharmacokinetic Interaction between Sorafenib and Dapagliflozin in Rats.
    Molecules (Basel, Switzerland), 2022, Sep-21, Volume: 27, Issue:19

    Topics: Acetonitriles; Animals; Benzhydryl Compounds; Carcinoma, Hepatocellular; Chromatography, High Pressure Liquid; Chromatography, Liquid; Diabetes Mellitus, Type 2; Glucose; Glucosides; Glucuronosyltransferase; Liver Neoplasms; Rats; Reproducibility of Results; RNA, Messenger; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Sorafenib; Tandem Mass Spectrometry; Uridine Diphosphate

2022